PinkDx Develops Vaginal Swab Test to Reduce Endometrial Cancer Biopsies

On October 30, 2026, the Washington Post reported that American biotechnology company PinkDx is developing an innovative vaginal swab test that analyzes DNA and RNA fragments to detect molecular signatures of endometrial cancer in women experiencing abnormal uterine bleeding.

Key Clinical Takeaways:

• PinkDx is developing a molecular vaginal swab test for women with abnormal uterine bleeding, including postmenopausal bleeding.
• The diagnostic approach detects tumor-derived DNA and RNA without requiring a traditional, invasive in-office endometrial biopsy.
• A multi-center clinical validation study involving roughly 3,000 participants is currently underway across 16 medical centers in the United States.

The Diagnostic Challenge of Abnormal Uterine Bleeding

For patients presenting with abnormal vaginal bleeding, ruling out endometrial cancer remains a critical diagnostic priority. Clinicians traditionally rely on transvaginal ultrasound examinations to assess endometrial thickness, paired with tissue biopsies to identify malignancies or precancerous conditions. However, both standard evaluation methods frequently induce patient discomfort or pain. Conventional endometrial biopsies occasionally fail to yield sufficient tissue specimens, particularly among postmenopausal women where failure rates reach approximately 30 percent due to overly thin endometria or stenotic cervical canals.

Endometrial cancer develops within the inner lining of the uterus, with abnormal bleeding serving as a primary indicator—particularly when bleeding recurs after menopause. Recent epidemiological data show that endometrial cancer mortality rates continue to rise, driven partly by an increase in aggressive "non-endometrial-like" cancer subtypes that disproportionately impact Black women.

Molecular Detection via Vaginal Swab Samples

The diagnostic technology developed by PinkDx analyzes clinical vaginal swab samples to identify genetic material linked to endometrial tumors. When malignant cells within the uterine cavity die, they shed tumor-specific DNA and RNA fragments. These molecular signatures travel down the female reproductive tract into the vagina, where collection swabs capture them for laboratory analysis. Initial research analyzing 27 surgical patients demonstrated that genetic material originating from high-position uterine tumors remains detectable even when swabs are collected near the vaginal opening.

Bonnie Anderson, chief executive officer of PinkDx, emphasized that the clinical significance lies in securing cancer-identifying signals without requiring direct instrumentation inside the uterine cavity. To evaluate diagnostic accuracy definitively, the company launched the PROACTION multi-center clinical validation study across 16 U.S. medical centers, targeting an enrollment pool of approximately 3,000 women.

PinkDx Test Shows High Sensitivity but Requires Biopsy Confirmation

Preliminary findings released by PinkDx indicate a test sensitivity of 90 percent or higher, paired with a target specificity of at least 50 percent. Sensitivity measures the assay's capability to correctly identify patients with cancer, while specificity determines its accuracy in identifying individuals free of disease.

Despite eliminating the need for an initial tissue biopsy in eligible cases, positive test results still require conventional endometrial biopsies or secondary procedures for confirmation. Conversely, patients with negative test results who experience persistent abnormal bleeding must continue standard medical evaluations, as benign conditions such as uterine fibroids, polyps, and perimenopausal hormonal fluctuations also trigger abnormal bleeding. Researchers stress that this molecular assay functions strictly as a diagnostic aid for symptomatic patients rather than a generalized screening tool for asymptomatic populations.

Anderson anticipates completing certification from the Centers for Medicare & Medicaid Services (CMS) by early next year, targeting patient availability by mid-2027. Commenting on this development timeline, Wentzensen stated that the schedule is ambitious yet achievable, contingent upon larger-scale studies confirming the methodology’s real-world efficacy.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.